1e
19
1
49
2
2
18
1b
1d
18
32
5e
1d
2 29
1d
25
Stephanie Jean, M.D.
88
5e
Assistant Professor of Clinical Obstetrics and Gynecology
28
95
3
70
Attending Physician, Division of Gynecologic Oncology, Pennsylvania Hospital, Philadelphia, PA
af
Attending Physician, Division of Gynecologic Oncology, Chester County Hospital, Abramson Cancer Center, West Chester, PA
a0
Attending Physician, Division of Gynecologic Oncology, Penn Presbyterian Medical Center, Philadelphia, PA
aa
Attending Physician, Division of Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
11
Department: Obstetrics and Gynecology
4
1
b
1d
46
Contact information
51
4
3
3
3
2
4
b
1f
51
Abramson Cancer Center West Chester
44 440 E. Marshall Street, Suite 101
West Chester, PA 19380
26
44 440 E. Marshall Street, Suite 101
West Chester, PA 19380
2e
Office: 800-789-7366
30
f
30
13
Education:
21 9 B.S. 37 (Departmental Honors in Biological Sciences) c
3a Stanford University, Stanford, CA, 2002.
21 7 MD 1e (Alpha Omega Alpha) c
68 State University of New York at Stony Brook School of Medicine, Stony Brook, NY, 2007.
c
3
3
3
3
8d
Permanent link21 9 B.S. 37 (Departmental Honors in Biological Sciences) c
3a Stanford University, Stanford, CA, 2002.
21 7 MD 1e (Alpha Omega Alpha) c
68 State University of New York at Stony Brook School of Medicine, Stony Brook, NY, 2007.
c
2 29
21
1e
1d
24
2b
29
27
23
13d Nacarelli T, Fukumoto T, Zundell JA, Fatkhutdinov N, Jean S, Cadungog MG, Borowsky ME, Zhang R: NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer. Cancer Res 80(4):890-900, Feb 2020.
173 Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N, Park PH, Semenova G, Jean S, Cadungog MG, Borowsky ME, Kossenkov AV, Liu Q, Zhang R: EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition. Cancer Cell 37(2):157-167.e6, Feb 2020.
164 Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, Zundell J, Fukumoto T, Liu Q, Kossenkov A, Jean S, Cadungog MG, Borowsky ME, Drapkin R, Lieberman PM, Abate-Shen CT, Zhang R: ARID1A promotes genomic stability through protecting telomere cohesion. Nat Commun 10(1):4067, Sep 2019.
146 Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R: N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res 79(11):2812-2820, Jun 2019.
155 Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW: CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Sci Rep 8(1):14725, Oct 2018.
157 Fukumoto T, Park P, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang T, Shih I, Conejo-Garcia JR, Bitler BG, Zhang R: Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22(13):3393-3400, Mar 2018.
1a0 George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F: A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2(1):e89760, Jan 2017.
179 Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, Mclane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi, JL: Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget 7(30):48577-48585, Jul 2016.
19b Jean S, Li J, Wubbenhorst B, Maxwell KN, Fishbein L, Mclane MW, Mitra N, Zhang L, Nathanson KL, Tanyi, JL: Paclitaxel is necessary for improved survival in epithelial ovarian cancers with somatic homologous recombination gene mutations. Abstract presented, American Association for Cancer Research Annual Meeting, Washington, DC Apr 2015.
2c
7
1d
1f
Selected Publications
251 Dai Y, Knisely A, Yano M, Dang M, Hinchcliff EM, Lee S, Welp A, Chelvanambi M, Matthew Lastrapes M, Liu H, Yuan Z, Wang C, Nie H, Jean S, Montaner LJ, Hou J, Patel A, Patel S, Fellman B, Yuan Y, Sun B, Pandurengan RK, Cuentas ERP, Celestino J, Liu Y, Liu J, Hillman RT, Westin SN, Sood AK, Soliman PT, Shafer A, Meyer LA, Gershenson DM, Vining D, Ganeshan D, Lu K, Wargo JA, Peng W, Zhang R, Wang L, Jazaeri AA: PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 644(8076):537-546, Aug 2025.13d Nacarelli T, Fukumoto T, Zundell JA, Fatkhutdinov N, Jean S, Cadungog MG, Borowsky ME, Zhang R: NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer. Cancer Res 80(4):890-900, Feb 2020.
173 Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N, Park PH, Semenova G, Jean S, Cadungog MG, Borowsky ME, Kossenkov AV, Liu Q, Zhang R: EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition. Cancer Cell 37(2):157-167.e6, Feb 2020.
164 Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, Zundell J, Fukumoto T, Liu Q, Kossenkov A, Jean S, Cadungog MG, Borowsky ME, Drapkin R, Lieberman PM, Abate-Shen CT, Zhang R: ARID1A promotes genomic stability through protecting telomere cohesion. Nat Commun 10(1):4067, Sep 2019.
146 Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R: N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res 79(11):2812-2820, Jun 2019.
155 Singha B, Harper SL, Goldman AR, Bitler BG, Aird KM, Borowsky ME, Cadungog MG, Liu Q, Zhang R, Jean S, Drapkin R, Speicher DW: CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Sci Rep 8(1):14725, Oct 2018.
157 Fukumoto T, Park P, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang T, Shih I, Conejo-Garcia JR, Bitler BG, Zhang R: Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22(13):3393-3400, Mar 2018.
1a0 George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F: A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2(1):e89760, Jan 2017.
179 Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, Mclane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi, JL: Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget 7(30):48577-48585, Jul 2016.
19b Jean S, Li J, Wubbenhorst B, Maxwell KN, Fishbein L, Mclane MW, Mitra N, Zhang L, Nathanson KL, Tanyi, JL: Paclitaxel is necessary for improved survival in epithelial ovarian cancers with somatic homologous recombination gene mutations. Abstract presented, American Association for Cancer Research Annual Meeting, Washington, DC Apr 2015.
2c